Ponatinib

Gastrointestinal stromal tumors (GIST)

About Gastrointestinal Stromal Tumors.

According to the American Cancer Society, approximately 4,000 to 5,000 people develop gastrointestinal stromal tumors (GIST) each year in the United States. Approved agents for the treatment of patients with GIST include imatinib for newly diagnosed patients, sunitinib for patients in whom imatinib has failed, and regorafenib for patients who have failed imatinib and sunitinib. Patients can develop resistance to any of these therapies by acquiring secondary KIT mutations. A Phase II trial of ponatinib in GIST is ongoing and enrolling patients.